NCI-H3122 Cells

The NCI-H3122 cell line is derived from non-small-cell lung cancer (NSCLC) and is characterized by the presence of the EML4-ALK fusion gene, which results from a chromosomal translocation between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK). This fusion drives oncogenic signaling and makes NCI-H3122 cells highly dependent on ALK signaling for survival, known as “ALK-addicted.” NCI-H3122 has become a key model for studying targeted therapies, particularly for ALK inhibitors like crizotinib.
Studies have shown that NCI-H3122 cells are sensitive to crizotinib, which inhibits ALK phosphorylation and its downstream targets such as the AKT and ERK pathways. However, resistance to crizotinib often develops, typically due to alternative signaling pathways like the activation of the epidermal growth factor receptor (EGFR). This resistance mechanism has been confirmed in NCI-H3122 resistant variants, where increased EGFR phosphorylation was observed, and dual inhibition of ALK and EGFR using crizotinib and EGFR inhibitors such as afatinib or erlotinib was shown to overcome the resistance.
NCI-H3122 is frequently used to explore combination therapies aimed at preventing or reversing drug resistance. For instance, targeting both ALK and EGFR pathways has been a successful strategy in preclinical models, and this dual inhibition has been suggested as a potential therapeutic approach for ALK-positive, crizotinib-resistant NSCLC patients.